MOM

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic and risk assessment technologies for unmet clinical needs, today
announces that the non-binding Letter of Intent (the "LOI") the Company executed
with Cachet Pharmaceutical Co. Ltd. ("Cachet") on September 30, 2013, to provide
a non-exclusive 90-day negotiation period for Cachet to acquire an exclusive
license to commercialize the Company's Scout DS(R) Non-Invasive Diabetes
Screening Test in Mainland China, has been extended by mutual agreement of the
parties for an additional 30-day period ending January 30, 2014.


"The parties continue to engage in meaningful discussions regarding the
establishment and execution of a definitive licensing agreement," said
Christopher J. Moreau, President and CEO of Miraculins Inc. "Miraculins and
Cachet concur that additional time is required in order to further pursue
discussions."


Any licensing agreement advanced would be subject to satisfactory due diligence,
definitive documentation, and board approval by both parties respectively.


About Cachet Pharmaceutical Co. Ltd.

Founded in 1998, Cachet Pharmaceutical Co., Ltd. is a majority state-owned stock
company with a market capitalization of 4 Billion RMB ($654 Million USD).
Cachet's largest shareholder, the China Youth Industrial Development
Corporation, belongs directly to the Central Committee of the Communist Youth
League of China. On August 18, 2010, Cachet went public on the Shenzhen Stock
Exchange (stock name: Cachet; stock code: 002462). Cachet Pharmaceutical Co.,
Ltd. engages in the wholesale and retail sale of pharmaceutical products in
China. The company is involved in the supply of medicines to hospitals;
wholesale of biological products, medical instruments, and traditional Chinese
medicines; and pharmaceutical logistics. It additionally owns 150 chain stores
in Beijing that sell medicines, health care food, medical instruments,
cosmetics, daily necessities, and traditional Chinese medicines.


Diabetes in China

A recent nationwide survey conducted in China indicates that 11.6% of adults, or
114 million people, has diabetes. The data, published in the Journal of the
American Medical Association, additionally projects that 40% of 18-20 year olds
and 47% of 30-39 year olds in China are pre-diabetic, and that 493.4 million
people have higher than normal blood glucose levels (as diagnosed by fasting
blood glucose and Hba1C testing). According to the World Health Organization,
over time diabetes can damage the heart, blood vessels, eyes, kidneys, and
nerves and it increases the risk of heart disease and stroke (50% of people with
diabetes die of cardiovascular disease - primarily heart disease and stroke).
Combined with reduced blood flow, neuropathy (nerve damage) in the feet
increases the chance of foot ulcers, infection and eventual need for limb
amputation. Diabetic retinopathy is an important cause of blindness, and occurs
as a result of long-term accumulated damage to the small blood vessels in the
retina. One percent of global blindness can be attributed to diabetes, diabetes
is among the leading causes of kidney failure and the overall risk of dying
among people with diabetes is at least double the risk of their peers without
diabetes. The financial burden of diabetes and its complications is also
enormous.


About the Scout DS(R) System

The Scout DS(R) system, is the first non-invasive diabetes testing system
designed to provide a highly sensitive and convenient method for measuring
diabetes related biomarkers in the skin, the accumulation of which are
accelerated by abnormal blood sugar levels and oxidative stress. Unlike current
testing methods, a Scout DS(R) test requires no blood draw, no fasting, and no
waiting for a lab result. The product has been used and validated in thousands
of patients around the world.


About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive technologies for unmet clinical needs. A
significant number of promising diagnostic opportunities remain
un-commercialized because of the sizable gap between the discovery stage, when
research institutions are typically involved, and the commercialization stage,
when the larger commercial enterprises become interested. Miraculins has direct
experience in bridging this gap. The Company's PreVu(R) POC Test is a
revolutionary new coronary artery disease risk assessment technology that
measures cholesterol levels in a patient's skin non-invasively, painlessly and
without the need for fasting. The Company's Scout DS(R) system is the first
non-invasive diabetes testing system designed to provide a highly sensitive and
convenient method for measuring diabetes related biomarkers in the skin, the
accumulation of which are accelerated by abnormal blood sugar levels and
oxidative stress. Unlike current testing methods, a Scout DS(R) test requires no
blood draw, no fasting, and no waiting for a lab result. The product has been
used and validated in thousands of patients around the world. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's largest
diagnostic companies. For more information visit www.miraculins.com.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements include statements regarding entering into and executing a definitive
licensing agreement. These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions, plans, beliefs,
estimates and outlook, including, without limitation, our anticipated future
operating results, and can, in some cases, be identified by the use of words
such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and
other similar expressions. In addition, any statements that refer to
expectations, projections or other characterizations of future events or
circumstances are forward-looking statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statement.


PreVu(R) and Scout DS(R) are registered trademarks of Miraculins Inc. All Rights
Reserved. 2013.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Miraculins Inc. (TSXV:MOM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024